Stock LLY ELI LILLY AND COMPANY
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Eli Lilly and Company Deutsche Boerse AG

Equities

LLY

US5324571083

Market Closed - Deutsche Boerse AG
Other stock markets
 12:33:10 2024-06-06 pm EDT 		5-day change 1st Jan Change
770 EUR +0.33% Intraday chart for Eli Lilly and Company +2.57% +46.25%
Jun. 06 US FDA panel to vote on data, risk profile of Lilly Alzheimer's drug RE
Jun. 06 Novo Nordisk braces for generic challenge to Ozempic, Wegovy in China RE

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
US FDA panel to vote on data, risk profile of Lilly Alzheimer's drug
Novo Nordisk braces for generic challenge to Ozempic, Wegovy in China
Alphabet ficha a Anat Ashkenazi, directora financiera de Eli Lilly, para suceder a Ruth Porat
Alphabet Appoints Anat Ashkenazi as CFO
Eli Lilly CFO Anat Ashkenazi Resigns
Campbell Soup, HPE, Intel... Les valeurs à suivre aujourd'hui à Wall Street
Eli-Lilly-Managerin wird Finanzchefin bei Google-Mutter Alphabet
Eli Lilly: Départ de la directrice financière Anat Ashkenazi
Alphabet : la directrice financière d'Eli Lilly recrutée
Alphabet names Eli Lilly executive Anat Ashkenazi as CFO
Eli Lilly finance chief to leave company
Eli Lilly and Company Announces Resignation of Anat Ashkenazi as Executive Vice President
UK Stocks-Factors to watch on June 6
UK Institute Makes Draft Recommendation for Eli Lilly's Weight-loss Drug With No Time Limit
Britain considers offering Lilly weight-loss drug on better terms than Wegovy
Eli Lilly : recrute la directrice qualité de Bristol Myers
Eli Lilly and Company Appoints Melissa Seymour as Executive Vice President of Global Quality and Member of the Executive Committee, Effective July 22, 2024
Eli Lilly : données encourageantes autour de l'olomorasib
Structure Therapeutics' obesity drug meets main goal in mid-stage study
Eli Lilly and Company Announces Updated Data from the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors Presented at the 2024 ASCO® Annual Meeting
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LLY Stock
  4. LLY Stock
  5. News Eli Lilly and Company
  6. Other languages